PLG Journal

PLG Journal: Issue 23 – September 2015

PLG Journal Issue 23: September 2015

Members: login to access current and past issues of the Business Development & Licensing Journal.

In this issue...

Outgrowing the Thread of a Takeover

Barbara Krebs-Pohl, Senior Vice President, Head of Business Development, MorphoSys AG

As a biopharmaceutical company with attractive proprietary compounds, becoming a potential M&A target for larger pharmaceutical companies is eventually a standard business scenario. Even more so when the company possesses a strong underlying proprietary drug discovery platform and related expertise. MorphoSys has prospered in such a situation through many years although the acquisition of the Company was, according to some external spectators at least, constantly just around the next corner.

Post-Deal Execution: Ensuring the maximum value for your deal

Steve Twait, VP, Alliance and Integration Management (AIM), AstraZeneca

Since different types of deals (co-development, co-commercialisation, acquisitions and divestments) have different resource requirements post-signing, business development professionals should take this into consideration when negotiating a deal. The best means to accomplish this is to involve an alliance management professional from the start.

Key Issues for Cross-Border Deals

Greg Benning, Managing Director & Group Head of the Financial Advisory Practice and Mark King, Senior Partner, Back Bay Life Science Advisors LLC”

Deal-making in Volatile Markets
2015 life science licensing and acquisitions will inevitably conclude with record-setting overall transaction volumes, dominated by mega-deals driven by strategic goals of scale and capital efficiency. Emerging and mid-size deals however, tend to be driven by considerations of who, in terms of organisational capacity and capital, is the best owner of an asset at a given stage of scientific, clinical or commercial development. Large cap global M&A is impacted by monetary policy, regional economic outlook and institutional capital flows. On the other hand, emerging and mid-size deals require sophisticated project investment, risk management and option valuation skills.

Medius Deal Watch

Sharon Finch, CEO, Medius Associates

This month, some companies seem determined to prove that not all of Europe closes for business and disappears off to the beach during August! Very deal busy and present in the headlines were AstraZeneca, Sanofi and Shire with a range of deals, bids and acquisitions.